RELEVANT EVENT

As a continuation of the relevant event number 261079 dated January 30, 2018, Grifols, S.A. ("Grifols") reports that the estimated impact of the recently enacted tax reform in the United States of America ("U.S.") on 22 December 2017 will result in the recognition of non-recurrent income of approximately US$200 million (Euros 170 million) in the consolidated financial statements of Grifols for the 2017 fiscal year.

Likewise, it is expected that this non-recurring income will be partially offset in the fourth quarter 2017 results by a total net amount of approximately Euros 80 million in consequence of a reassessment of assets related to Grifols participation in the U.S.-based company Aradigm, after it has not obtained the approval of its product Linhaliq™ by the U.S. FDA.

Considering both of these events, Grifols estimates a positive non-recurring impact that amounts to approximately Euros 90 million net in the consolidated results of the fourth quarter of 2017.

Details of the final actual impact are expected to be disclosed with the publication of the Grifols Group's fourth quarter 2017 results.

In Barcelona, on 30 January de 2018

Nuria Martín Barnés
Secretary to the Board of Directors